

**INTERIM REPORT  
for I-VI 2023  
Medika Group**

**June 2023**

---

## Management interim report

### **Comment on the business results for the first half of 2023**

Medika Group („Group“) has realised total revenue in the first six months of 2023 in amount of EUR 369.3 million which is by 22.48% higher comparing to the same period of previous year. The increase in total revenues is a result of market growth and increased sales.

Sales revenues which amount to EUR 365.7 million for the first six months of 2023 are by 22.94% higher comparing to the same period of previous year.

Share of sales revenues in the total revenue is 99.04% while in the same period of previous year it was 98.67%.

Other operating revenues which amount to EUR 2.1 million are lower by 13.35% compared to the same period of previous year. Share of other operating revenues in total revenue was 0.80% in the first six months of previous year, and in the first six months of 2023 is 0.57%.

Out of the total sales revenues in the first six months of 2023, 99.57% revenues are generated on domestic market, while 0.43% is generated on the foreign market. In the first six months of 2022, 99.75% revenues were generated on domestic market, while 0.25% were generated on the foreign market.

Material expenses amount to EUR 343.3 million and are 22.98% higher comparing to the same period of previous year, which is in accordance with the increase of sales. The share of material expenses in the operating expenses is higher by 0.40 percentage points compared to the same period of previous year and amounts to 96.04%.

Employee expenses are higher by 6.90% compared to the same period of previous year. Their share in the total expenses amounts to 2.44% and decreased by 0.35 percentage points compared to the same period previous year. This increase of employee expenses was affected by the average number of employees which is higher in the first six months of 2023 compared to the same period of the previous year and salary increase during 2022 and 2023.

Financial income has decreased compared to the same period of the previous year for EUR 122 thousand, or 8.81% lower compared to the same period of the previous year. Finance income relates entirely to interest income. This decrease was affected by the decrease in income from penalty interest due to the collection of receivables from hospital lawsuits compared to the same period of the previous year.

Financial expenses have increased compared to the same period of previous year by EUR 429 thousand, which is 240.65%. Their share in total expenditures is 0.17%. This increase was affected by higher average credit indebtedness and higher average contracted interest rate compared to the realized average indebtedness and realised average interest rate in the same period of the previous year.



Gross margin in the first six months of 2022 amounted to 7.15%, while in the first six months of 2023 amounts to 7.01%, which is a decrease by 0.14 percentage points.

Gross profit (profit before taxation) amounts to EUR 11.3 million, while in the same period of previous year amounted to EUR 9.5 million, which is an increase of EUR 1.8 million, or 18.79%. Higher gross profit is result of lower growth of total expenses (increase of EUR 66.0 million comparing to the same period of previous year mostly due to the increase in operating expenses) in relation to the increase of total income (increase of EUR 67.8 million comparing to the same period of previous year due to the increase in operating income).

Operative earnings amount to EUR 10.4 million and are by EUR 2.3 million, or 29.08% higher comparing to the same period of previous year. Higher operative earnings are result of higher operating income (increase of EUR 67.9 million comparing to the same period of previous year) in relation to realised operating expenses (which increased by EUR 65.6 million comparing to the same period of previous year).

Realised net profit amounts to EUR 9.3 million.

Transactions with the related parties in the first six months of 2023 generated total net revenues in amount of EUR 5.3 million, which is 109.33% higher compared to generated revenue in the same period of previous year when it amounted to EUR 2.5 million. The increase is a result of increase sales in ZU Ljekarne Jagatić.

Trade goods purchased from the related parties amounts to EUR 24.4 million, while in the same period of previous year amounted to EUR 16.5 million, which is increase of EUR 7.9 million, or 48.00%.

Total assets amount to EUR 461.1 million which is by 13.61% higher comparing to the beginning of the year.

Long term assets did not significantly change compared to the beginning of the year. Non-current intangible assets amount to EUR 41.1 million which is an increase by 3.9% which was mostly significantly influenced by the purchase of a new pharmacy. Non-current tangible assets amount to EUR 30.8 million and is lower for EUR 187 thousand, or 0.60% compared to the beginning of the year, which was mostly affected by depreciation.

Long term financial assets mostly relate to investments in the associated company ZU Ljekarna Jagatić and long-term given cash loans. Long term financial assets amount to EUR 3.8 million and decreased by 3.46% compared to the beginning of the year, due to payments of given loans and profit payment from ZU Ljekarne Jagatić.

Long term receivables refer to the given merchandise loans to customers (merchandise loans are due receivables that are reprogrammed and the payment has been agreed in the future periods). Non-current receivables increased by 40.53% compared to the beginning of the year, due to issued new merchandise loans.

Short term assets amount to EUR 384.8 million which is 16.25% higher compared to the beginning of the year. In the structure of current assets, trade receivables and inventories have increased, while financial assets and cash have decreased compared to the beginning of the year.

Inventory amounts to EUR 69.0 million and has increased by EUR 7.0 million comparing to the beginning of the year, or 11.27%, which was affected by sales increase and higher number of pharmacies.

Total short-term receivables amount to EUR 292.1 million and are higher by EUR 77.7 million, or 36.22%, comparing to the beginning of the year. Trade receivables, receivables from related parties and receivables from participating parties amounts to EUR 290.1 million and have increased by 36.23% compared to the beginning of the year due to slower collection of receivables, increase in pharmacies payment days by the Croatian Institute for Health Insurance and sales growth.

Cash in bank amounts to EUR 23.5 million and record a decrease by EUR 30,7 million compared to the beginning of the year.

Long-term liabilities amount to EUR 12.3 million, out of which EUR 4.3 million relates to liabilities under operating leases (in accordance with IFRS 16 Leases), EUR 1.1 million relates to liabilities for received long-term loan, EUR 3.3 million to agreed instalments with supplier, EUR 2.8 million relates to deferred tax liability, EUR 778 thousand relates to finance lease liabilities and EUR 32 thousand to received long-term deposits. Long-term liabilities decreased by EUR 2.7 million compared to the beginning of the year.

Short term liabilities amount to EUR 349.3 million out of which the biggest part in amount of EUR 282.8 million relates to trade payables and EUR 57.8 million to credit indebtedness (EUR 57.3 million relates to short term loans and EUR 559 thousand to finance lease).

Trade payables are higher by EUR 43.6 million compared to the beginning of the year, or by 18.22%.

Total credit indebtedness of the Group amount to EUR 58.4 million which is an increase of EUR 11.3 million comparing to the beginning of the year, for the purposes of current liquidity and for the payment of trade payables due to a slower collection of receivables from customers. The credit indebtedness of the Medika Group refers entirely to the credit indebtedness of Medika d.d. while the Prima Pharma Group is not in debt. Of the total indebtedness, on 30 June 2023, EUR 1.1 million relates to long-term loan. With regard to the transition to the national currency of the euro at the beginning of 2023, there is no exposure to a foreign currency, given that all loans were converted to the euro as of 1 January 2023.



---

**Key events**

In the first six months of 2023, the pharmaceutical product market increased by 15.06% compared to the same period of the previous year. Medika's sales increased by 33.51% compared to the same period of the previous year, resulting in an increase in the market share of 5.22 percentage points, and it is 37.74%.

Credit indebtedness increased by EUR 11.3 million compared to the beginning of the year for the liquidity purposes.

The Government of the Republic of Croatia adopted the Decision on the announcement of the introduction of the euro as the official currency in the Republic of Croatia (published in "Official Gazette" No. 85/22). With the aforementioned decision, the euro becomes the official monetary unit and legal currency in the Republic of Croatia on 1 January 2023. The fixed conversion rate is set at HRK 7.53450 for one euro.

The summary financial statements were prepared on the basis of the same accounting policies, views and calculation methods used in the preparation of the annual financial statements as at 31 December 2022, with the conversion of the reporting currency for the comparative period at the conversion rate of 7.53450.

**Expected future development of the Group**

The Group will continue with its core business, distribution of medicinal products and medical devices and strongly develop operations with products that make the core business of the company.

The development strategy of ZU Prima Pharme is to expand the network of pharmacies throughout the territory of Croatia.

**Treasury shares**

As at 30 June 2023 Medika holds 1,240 treasury shares.

**Subsidiaries and associates**

The Company Medika d.d. has 100% ownership in subsidiaries Ljekarne Prima Pharme and Primus nekretnine d.o.o.

Ljekarne Prima Pharme has 100% ownership in subsidiary ZU Ljekarna Šeremet and an associate ZU Ljekarne Jagatić in which it holds 49% of ownership.

**Related parties**

The company with major voting rights, Auctor d.o.o. owns 48.04% of the Company and has 50.10% of shares with voting rights.

Pliva Hrvatska d.o.o., Zagreb owns 25.32% of the Company and has 26.41% of the voting rights. Given the share in the ownership and business transactions with the Company, Pliva Hrvatska has significant influence on the current operations of the Company.

***Financial risks and exposure to price risk, credit risk, liquidity and cash flow risk***

The most significant market risk for the Group is the long collection period for trade receivables, especially HZZO (Croatian State Health Insurance) related receivables. Therefore, a significant amount of working capital is not available, which strongly affects the cash flow and timely settlement of Group's liabilities.

As the receivables represent, directly or indirectly, amounts owed by state institutions, their collection should not be regarded as probable of default risk. This indirectly increases the need for additional funding, which means additional business costs.

Credit risk arises primarily from trade receivables. The risk is higher when dealing with privately owned pharmacies. Hospitals, on the other hand, have extended collection periods, but there is no risk of non-settlement.

A part of the Group's assets are interest-bearing assets, as a result of which its revenue and investing cash flows depend on fluctuations in market interest rates.

The Group's interest rate risk arises from its short-term and long-term borrowings at variable rates. Variable-rate borrowings expose the Group to the interest-rate cash flow risk. Fixed-rate borrowings expose the Group to the interest-rate fair value risk.

Price risk arises from continuous decrease in the prices of prescription medicinal products on the HZZO list and administrative approach in determining the prices and margins of medicinal products. To lower this risk, the Group has focused on expanding the lines of products that are not limited by law in respect of the price of the product.

In accordance with the Decision on the announcement of the introduction of the euro as the official currency in the Republic of Croatia (published in the "Official Gazette" No. 85/22), the euro becomes the official monetary unit and legal tender in the Republic of Croatia on 1 January 2023, and consequently the Group has no significant currency risk.

Regarding EU restriction measures, which refers to the consequences of exposure and the impact of the Russian invasion of Ukraine, the Group declares that it does not have a direct business relationship with entities from Russia or Ukraine, nor it is otherwise directly exposed to those entities in its business.

Nevertheless, the Company's Management Board estimates that a direct impact on the Group operations is possible due to the impact of the entire economy on global level, mainly due to the increase in the price of the products, both raw materials, interest rates and inflation that have increased further with the Russian invasion of Ukraine. Given the uncertain extent of the impact of the economy, the Group monitors developments and assesses the impact on business financial situation and cash flows.

<sup>3</sup> **Medika** d.d.  
ZAGREB, Capraška 1

Jasminko Herceg, dipl.oec.  
*President of the Management Board*





## Annex 1

## ISSUER'S GENERAL DATA

Reporting period:

1.1.2023

to

30.6.2023

Year:

2023

Quarter:

2.

## Quarterly financial statements

Registration number (MB):

03209741

Issuer's home Member

State code:

HR

Entity's registration  
number (MBS):

080027531

Personal identification  
number (OIB):

94818858923

LEI:

7478000000R8ZVGJJO27

Institution  
code:

1339

Name of the issuer: **MEDIKA d.d.**

Postcode and town:

10000

ZAGREB

Street and house number: **CAPRAŠKA 1**E-mail address: **medika.uprava@medika.hr**Web address: **www.medika.hr**Number of employees  
(end of the reporting

962

Consolidated report:

KD

(KN-not consolidated/KD-consolidated)

Audited:

RN

(RN-not audited/RD-audited)

Names of subsidiaries (according to IFRS):

Registered office:

MB:

Ljekarne Prima Pharme

Zagreb

0694975

Primus nekretnine d.o.o.

Zagreb

4439856

Zdravstvena ustanova Ljekarna Šeremet

Zagreb

1324870

Bookkeeping firm:

(Yes/No)

(name of the bookkeeping firm)

Contact person: **INES BOSNAR ŠMITUC**

(only name and surname of the contact person)

Telephone: **01/2412 551**E-mail address: **medika.uprava@medika.hr**

Audit firm:

(name of the audit firm)

Certified auditor:

(name and surname)

<sup>3</sup> **Medika** d.d.  
ZAGREB, Capraška 1

AB f. h



**BALANCE SHEET**  
balance as at 30.06.2023

in EUR

Submitter: Group Medika			
Item	ADP code	Last day of the preceding business year	At the reporting date of the current period
1	2	3	4
<b>A) RECEIVABLES FOR SUBSCRIBED CAPITAL UNPAID</b>	<b>001</b>	0	0
<b>B) FIXED ASSETS (ADP 003+010+020+031+036)</b>	<b>002</b>	74.751.251	76.084.448
<b>I INTANGIBLE ASSETS (ADP 004 to 009)</b>	<b>003</b>	39.545.931	41.088.773
1 Research and development	004	0	0
2 Concessions, patents, licences, trademarks, software and other rights	005	28.642.644	27.906.995
3 Goodwill	006	10.862.874	12.632.227
4 Advances for the purchase of intangible assets	007	33.148	479.601
5 Intangible assets in preparation	008	7.265	69.950
6 Other intangible assets	009	0	0
<b>II TANGIBLE ASSETS (ADP 011 to 019)</b>	<b>010</b>	30.978.881	30.792.403
1 Land	011	4.034.817	4.034.817
2 Buildings	012	16.492.762	16.098.279
3 Plant and equipment	013	3.137.133	2.968.098
4 Tools, working inventory and transportation assets	014	894.118	825.163
5 Biological assets	015	0	0
6 Advances for the purchase of tangible assets	016	73.721	149.061
7 Tangible assets in preparation	017	6.233.805	6.605.024
8 Other tangible assets	018	112.525	111.961
9 Investment property	019	0	0
<b>III FIXED FINANCIAL ASSETS (ADP 021 to 030)</b>	<b>020</b>	3.898.087	3.763.400
1 Investments in holdings (shares) of undertakings within the group	021	0	0
2 Investments in other securities of undertakings within the group	022	0	0
3 Loans, deposits, etc. to undertakings within the group	023	0	0
4. Investments in holdings (shares) of companies linked by virtue of participating interests	024	3.449.155	3.381.834
5 Investment in other securities of companies linked by virtue of participating interests	025	0	0
6 Loans, deposits etc. to companies linked by virtue of participating interests	026	0	0
7 Investments in securities	027	0	0
8 Loans, deposits, etc. given	028	448.932	381.566
9 Other investments accounted for using the equity method	029	0	0
10 Other fixed financial assets	030	0	0
<b>IV RECEIVABLES (ADP 032 to 035)</b>	<b>031</b>	199.709	280.643
1 Receivables from undertakings within the group	032	0	0
2 Receivables from companies linked by virtue of participating interests	033	0	0
3 Customer receivables	034	199.709	280.643
4 Other receivables	035	0	0
<b>V DEFERRED TAX ASSETS</b>	<b>036</b>	128.643	159.229
<b>C) CURRENT ASSETS (ADP 038+046+053+063)</b>	<b>037</b>	331.027.650	384.822.115
<b>I INVENTORIES (ADP 039 to 045)</b>	<b>038</b>	61.993.765	68.978.127
1 Raw materials and consumables	039	72.224	69.137
2 Work in progress	040	0	0
3 Finished goods	041	0	0
4 Merchandise	042	61.033.874	67.537.223
5 Advances for inventories	043	887.667	1.371.767
6 Fixed assets held for sale	044	0	0
7 Biological assets	045	0	0
<b>II RECEIVABLES (ADP 047 to 052)</b>	<b>046</b>	214.408.171	292.070.912
1 Receivables from undertakings within the group	047	100	100
2 Receivables from companies linked by virtue of participating interests	048	3.505.036	4.364.556
3 Customer receivables	049	209.437.383	285.728.014

AB n.

4 Receivables from employees and members of the undertaking	050	393	362
5 Receivables from government and other institutions	051	492.336	815.459
6 Other receivables	052	972.923	1.162.421
<b>III CURRENT FINANCIAL ASSETS (ADP 054 to 062)</b>	<b>053</b>	<b>448.054</b>	<b>315.059</b>
1 Investments in holdings (shares) of undertakings within the group	054	0	0
2 Investments in other securities of undertakings within the group	055	0	0
3 Loans, deposits, etc. to undertakings within the group	056	0	0
4 Investments in holdings (shares) of companies linked by virtue of participating interests	057	0	0
5 Investment in other securities of companies linked by virtue of participating interests	058	0	0
6 Loans, deposits etc. to companies linked by virtue of participating interests	059	0	0
7 Investments in securities	060	0	0
8 Loans, deposits, etc. given	061	448.054	315.059
9 Other financial assets	062	0	0
<b>IV CASH AT BANK AND IN HAND</b>	<b>063</b>	<b>54.177.660</b>	<b>23.458.017</b>
<b>D ) PREPAID EXPENSES AND ACCRUED INCOME</b>	<b>064</b>	<b>101.354</b>	<b>202.078</b>
<b>E) TOTAL ASSETS (ADP 001+002+037+064)</b>	<b>065</b>	<b>405.880.255</b>	<b>461.108.641</b>
<b>OFF-BALANCE SHEET ITEMS</b>	<b>066</b>	<b>19.504.191</b>	<b>18.520.523</b>
<b>LIABILITIES</b>			
<b>A) CAPITAL AND RESERVES (ADP 068 to 070+076+077+083+086+089)</b>	<b>067</b>	<b>95.364.448</b>	<b>98.728.238</b>
I INITIAL (SUBSCRIBED) CAPITAL	068	27.771.507	27.778.480
II CAPITAL RESERVES	069	-282.844	-282.844
III RESERVES FROM PROFIT (ADP 071+072-073+074+075)	070	11.067.694	11.067.694
1 Legal reserves	071	2.461.810	2.461.810
2 Reserves for treasury shares	072	6.478.463	6.478.463
3 Treasury shares and holdings (deductible item)	073	-2.081.712	-2.081.712
4 Statutory reserves	074	0	0
5 Other reserves	075	4.209.133	4.209.133
IV REVALUATION RESERVES	076	0	0
V FAIR VALUE RESERVES AND OTHER (ADP 078 to 082)	077	0	0
1 Financial assets at fair value through other comprehensive income (i.e. available for sale)	078	0	0
2 Cash flow hedge - effective portion	079	0	0
3 Hedge of a net investment in a foreign operation - effective portion	080	0	0
4 Other fair value reserves	081	0	0
5 Exchange differences arising from the translation of foreign operations (consolidation)	082	0	0
VI RETAINED PROFIT OR LOSS BROUGHT FORWARD (ADP 084-085)	083	41.313.534	50.823.045
1 Retained profit	084	41.313.534	50.823.045
2 Loss brought forward	085	0	0
VII PROFIT OR LOSS FOR THE BUSINESS YEAR (ADP 087-088)	086	15.494.557	9.341.863
1 Profit for the business year	087	15.494.557	9.341.863
2 Loss for the business year	088	0	0
VIII MINORITY (NON-CONTROLLING) INTEREST	089	0	0
<b>B) PROVISIONS (ADP 091 to 096)</b>	<b>090</b>	<b>160.294</b>	<b>160.294</b>
1 Provisions for pensions, termination benefits and similar obligations	091	160.294	160.294
2 Provisions for tax liabilities	092	0	0
3 Provisions for ongoing legal cases	093	0	0
4 Provisions for renewal of natural resources	094	0	0
5 Provisions for warranty obligations	095	0	0
6 Other provisions	096	0	0
<b>C) LONG-TERM LIABILITIES (ADP 098 to 108)</b>	<b>097</b>	<b>14.980.828</b>	<b>12.300.953</b>
1 Liabilities to undertakings within the group	098	0	0
2 Liabilities for loans, deposits, etc. of undertakings within the group	099	0	0
3 Liabilities to companies linked by virtue of participating interests	100	0	0

AB π.



4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	101	0	0
5 Liabilities for loans, deposits etc.	102	32.328	32.328
6 Liabilities to banks and other financial institutions	103	3.312.714	1.919.261
7 Liabilities for advance payments	104	0	0
8 Liabilities to suppliers	105	4.250.025	3.250.005
9 Liabilities for securities	106	0	0
10 Other long-term liabilities	107	4.572.573	4.286.171
11 Deferred tax liability	108	2.813.188	2.813.188
<b>D) SHORT-TERM LIABILITIES (ADP 110 to 123)</b>	<b>109</b>	<b>294.945.188</b>	<b>349.341.786</b>
1 Liabilities to undertakings within the group	110	0	0
2 Liabilities for loans, deposits, etc. of undertakings within the group	111	0	0
3 Liabilities to companies linked by virtue of participating interests	112	16.368.255	18.437.149
4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	113	0	0
5 Liabilities for loans, deposits etc.	114	0	0
6 Liabilities to banks and other financial institutions	115	45.491.803	57.840.635
7 Liabilities for advance payments	116	354.768	8.016
8 Liabilities to suppliers	117	222.861.695	264.376.556
9 Liabilities for securities	118	0	0
10 Liabilities to employees	119	2.151.596	1.799.384
11 Taxes, contributions and similar liabilities	120	6.200.719	3.836.019
12 Liabilities arising from the share in the result	121	5.804	3.877
13 Liabilities arising from fixed assets held for sale	122	0	250.000
14 Other short-term liabilities	123	1.510.548	2.790.150
<b>E) ACCRUALS AND DEFERRED INCOME</b>	<b>124</b>	<b>429.497</b>	<b>577.370</b>
<b>F) TOTAL – LIABILITIES (ADP 067+090+097+109+124)</b>	<b>125</b>	<b>405.880.255</b>	<b>461.108.641</b>
<b>G) OFF-BALANCE SHEET ITEMS</b>	<b>126</b>	<b>19.504.191</b>	<b>18.520.523</b>

AB J.

**STATEMENT OF PROFIT OR LOSS**  
for the period 01.01.2023 to 30.06.2023

in EUR

Submitter: Group Medika

Item	ADP code	Same period of the previous year		Current period	
		Cumulative	Quarter	Cumulative	Quarter
1	2	3	4	5	6
<b>I OPERATING INCOME (ADP 002 to 006)</b>	<b>001</b>	<b>299.907.345</b>	<b>151.316.813</b>	<b>367.833.613</b>	<b>189.003.007</b>
1 Income from sales with undertakings within the group	002	0	0	0	0
2 Income from sales (outside group)	003	297.495.074	150.536.983	365.743.359	187.913.272
3 Income from the use of own products, goods and services	004	0	0	0	0
4 Other operating income with undertakings within the group	005	498	299	597	298
5 Other operating income (outside the group)	006	2.411.773	779.531	2.089.657	1.089.437
<b>II OPERATING EXPENSES (ADP 08+009+013+017+018+019+022+029)</b>	<b>007</b>	<b>291.830.948</b>	<b>148.004.956</b>	<b>357.408.586</b>	<b>183.519.013</b>
1 Changes in inventories of work in progress and finished goods	008	0	0	0	0
2 Material costs (ADP 010 to 012)	009	279.120.550	141.979.205	343.266.419	176.128.380
a) Costs of raw materials and consumables	010	1.135.091	563.687	988.041	460.743
b) Costs of goods sold	011	276.227.795	140.494.184	340.116.928	174.565.859
c) Other external costs	012	1.757.664	921.334	2.161.450	1.101.778
3 Staff costs (ADP 014 to 016)	013	8.143.070	4.148.207	8.704.835	4.471.624
a) Net salaries and wages	014	5.151.466	2.624.508	5.468.934	2.802.353
b) Tax and contributions from salary costs	015	2.016.162	1.030.867	2.170.194	1.121.336
c) Contributions on salaries	016	975.442	492.832	1.065.707	547.935
4 Depreciation	017	2.008.490	1.013.349	2.113.481	1.053.699
5 Other costs	018	2.461.005	802.955	3.085.002	1.807.064
6 Value adjustments (ADP 020+021)	019	97.833	61.240	238.849	58.246
a) fixed assets other than financial assets	020	0	0	0	0
b) current assets other than financial assets	021	97.833	61.240	238.849	58.246
7 Provisions (ADP 023 to 028)	022	0	0	0	0
a) Provisions for pensions, termination benefits and similar obligations	023	0	0	0	0
b) Provisions for tax liabilities	024	0	0	0	0
c) Provisions for ongoing legal cases	025	0	0	0	0
d) Provisions for renewal of natural resources	026	0	0	0	0
e) Provisions for warranty obligations	027	0	0	0	0
f) Other provisions	028	0	0	0	0
8 Other operating expenses	029	0	0	0	0
<b>III FINANCIAL INCOME (ADP 031 to 040)</b>	<b>030</b>	<b>1.376.636</b>	<b>570.574</b>	<b>1.255.298</b>	<b>614.432</b>
1 Income from investments in holdings (shares) of undertakings within the group	031	0	0	0	0
2 Income from investments in holdings (shares) of companies linked by virtue of participating interests	032	0	0	0	0
3 Income from other long-term financial investment and loans granted to undertakings within the group	033	0	0	0	0
4 Other interest income from operations with undertakings within the group	034	0	0	0	0
5 Exchange rate differences and other financial income from operations with undertakings within the group	035	0	0	0	0
6 Income from other long-term financial investments and loans	036	0	0	0	0
7 Other interest income	037	1.376.636	570.574	1.255.298	614.432
8 Exchange rate differences and other financial income	038	0	0	0	0
9 Unrealised gains (income) from financial assets	039	0	0	0	0
10 Other financial income	040	0	0	0	0
<b>IV FINANCIAL EXPENSES (ADP 042 to 048)</b>	<b>041</b>	<b>178.117</b>	<b>70.755</b>	<b>606.764</b>	<b>427.303</b>
1 Interest expenses and similar expenses with undertakings within the group	042	0	0	0	0
2 Exchange rate differences and other expenses from operations with undertakings within the group	043	0	0	0	0
3 Interest expenses and similar expenses	044	166.696	109.257	606.764	427.303
4 Exchange rate differences and other expenses	045	11.421	-38.502	0	0
5 Unrealised losses (expenses) from financial assets	046	0	0	0	0
6 Value adjustments of financial assets (net)	047	0	0	0	0
7 Other financial expenses	048	0	0	0	0
<b>V SHARE IN PROFIT FROM UNDERTAKINGS LINKED BY VIRTUE OF PARTICIPATING INTERESTS</b>	<b>049</b>	<b>222.474</b>	<b>94.056</b>	<b>208.245</b>	<b>95.007</b>
<b>VI SHARE IN PROFIT FROM JOINT VENTURES</b>	<b>050</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>VII SHARE IN LOSS OF COMPANIES LINKED BY VIRTUE OF PARTICIPATING INTEREST</b>	<b>051</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>VIII SHARE IN LOSS OF JOINT VENTURES</b>	<b>052</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>IX TOTAL INCOME (ADP 001+030+049 +050)</b>	<b>053</b>	<b>301.506.455</b>	<b>151.981.443</b>	<b>369.297.156</b>	<b>189.712.446</b>
<b>X TOTAL EXPENDITURE (ADP 007+041+051 + 052)</b>	<b>054</b>	<b>292.009.065</b>	<b>148.075.711</b>	<b>358.015.350</b>	<b>183.946.316</b>
<b>XI PRE-TAX PROFIT OR LOSS (ADP 053-054)</b>	<b>055</b>	<b>9.497.390</b>	<b>3.905.732</b>	<b>11.281.806</b>	<b>5.766.130</b>
1 Pre-tax profit (ADP 053-054)	056	9.497.390	3.905.732	11.281.806	5.766.130

NB K.



2 Pre-tax loss (ADP 054-053)	057	0	0	0	0
<b>XII INCOME TAX</b>	<b>058</b>	<b>1.736.130</b>	<b>749.683</b>	<b>1.939.943</b>	<b>935.620</b>
<b>XIII PROFIT OR LOSS FOR THE PERIOD (ADP 055-059)</b>	<b>059</b>	<b>7.761.260</b>	<b>3.156.049</b>	<b>9.341.863</b>	<b>4.830.510</b>
1 Profit for the period (ADP 055-059)	060	7.761.260	3.156.049	9.341.863	4.830.510
2 Loss for the period (ADP 059-055)	061	0	0	0	0
<b>DISCONTINUED OPERATIONS (to be filled in by undertakings subject to IFRS only with discontinued operations)</b>					
<b>XIV PRE-TAX PROFIT OR LOSS OF DISCONTINUED OPERATIONS (ADP 063-064)</b>	<b>062</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Pre-tax profit from discontinued operations	063	0	0	0	0
2 Pre-tax loss on discontinued operations	064	0	0	0	0
<b>XV INCOME TAX OF DISCONTINUED OPERATIONS</b>	<b>065</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Discontinued operations profit for the period (ADP 062-065)	066	0	0	0	0
2 Discontinued operations loss for the period (ADP 065-062)	067	0	0	0	0
<b>TOTAL OPERATIONS (to be filled in only by undertakings subject to IFRS with discontinued operations)</b>					
<b>XVI PRE-TAX PROFIT OR LOSS (ADP 055-+062)</b>	<b>068</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Pre-tax profit (ADP 068)	069	0	0	0	0
2 Pre-tax loss (ADP 068)	070	0	0	0	0
<b>XVII INCOME TAX (ADP 058+065)</b>	<b>071</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>XVIII PROFIT OR LOSS FOR THE PERIOD (ADP 068-071)</b>	<b>072</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Profit for the period (ADP 068-071)	073	0	0	0	0
2 Loss for the period (ADP 071-068)	074	0	0	0	0
<b>APPENDIX to the P&amp;L (to be filled in by undertakings that draw up consolidated annual financial statements)</b>					
<b>XIX PROFIT OR LOSS FOR THE PERIOD (ADP 076+077)</b>	<b>075</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Attributable to owners of the parent	076	0	0	0	0
2 Attributable to minority (non-controlling) interest	077	0	0	0	0
<b>STATEMENT OF OTHER COMPREHENSIVE INCOME (to be filled in by undertakings subject to IFRS)</b>					
<b>I PROFIT OR LOSS FOR THE PERIOD</b>	<b>078</b>	<b>7.761.260</b>	<b>3.156.049</b>	<b>9.341.863</b>	<b>4.830.510</b>
<b>II OTHER COMPREHENSIVE INCOME/LOSS BEFORE TAX (ADP 80+ 87)</b>	<b>079</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>III Items that will not be reclassified to profit or loss (ADP 081 to 085)</b>	<b>080</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Changes in revaluation reserves of fixed tangible and intangible assets	081	0	0	0	0
2 Gains or losses from subsequent measurement of equity instruments at fair value through other comprehensive income	082	0	0	0	0
3 Fair value changes of financial liabilities at fair value through statement of profit or loss, attributable to changes in their credit risk	083	0	0	0	0
4 Actuarial gains/losses on the defined benefit obligation	084	0	0	0	0
5 Other items that will not be reclassified	085	0	0	0	0
6 Income tax relating to items that will not be reclassified	086	0	0	0	0
<b>IV Items that may be reclassified to profit or loss (ADP 088 to 095)</b>	<b>087</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Exchange rate differences from translation of foreign operations	088	0	0	0	0
2 Gains or losses from subsequent measurement of debt securities at fair value through other comprehensive income	089	0	0	0	0
3 Profit or loss arising from effective cash flow hedging	090	0	0	0	0
4 Profit or loss arising from effective hedge of a net investment in a foreign operation	091	0	0	0	0
5 Share in other comprehensive income/loss of companies linked by virtue of participating interests	092	0	0	0	0
6 Changes in fair value of the time value of option	093	0	0	0	0
7 Changes in fair value of forward elements of forward contracts	094	0	0	0	0
8 Other items that may be reclassified to profit or loss	095	0	0	0	0
9 Income tax relating to items that may be reclassified to profit or loss	096	0	0	0	0
<b>V NET OTHER COMPREHENSIVE INCOME OR LOSS (ADP 080+087-086 - 096)</b>	<b>097</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>VI COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 078+097)</b>	<b>098</b>	<b>7.761.260</b>	<b>3.156.049</b>	<b>9.341.863</b>	<b>4.830.510</b>
<b>APPENDIX to the Statement on comprehensive income (to be filled in by undertakings that draw up consolidated statements)</b>					
<b>VI COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 100+101)</b>	<b>099</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Attributable to owners of the parent	100	0	0	0	0
2 Attributable to minority (non-controlling) interest	101	0	0	0	0

9/5

7.



**STATEMENT OF CASH FLOWS - indirect method**  
for the period 01.01.2023 to 30.06.2023

in EUR

Submitter: Group Medika				
Item	ADP code	Same period of the previous year	Current period	
1	2	3	4	
<b>Cash flow from operating activities</b>				
1 Pre-tax profit	001	9.497.390	11.281.806	
2 Adjustments (ADP 003 to 010):	002	499.847	2.055.037	
a) Depreciation	003	2.008.490	2.113.481	
b) Gains and losses from sale and value adjustment of fixed tangible and intangible assets	004	-786.295	-54.673	
c) Gains and losses from sale and unrealised gains and losses and value adjustment of financial assets	005	97.833	238.849	
d) Interest and dividend income	006	-1.376.636	-1.255.298	
e) Interest expenses	007	166.696	606.764	
f) Provisions	008	0	0	
g) Exchange rate differences (unrealised)	009	-176.418	866	
h) Other adjustments for non-cash transactions and unrealised gains and losses	010	566.177	405.048	
<b>I Cash flow increase or decrease before changes in working capital (ADP 001+002)</b>	<b>011</b>	<b>9.997.237</b>	<b>13.336.843</b>	
3 Changes in the working capital (ADP 013 to 016)	012	-30.940.466	-42.421.697	
a) Increase or decrease in short-term liabilities	013	27.935.145	42.619.706	
b) Increase or decrease in short-term receivables	014	-47.990.842	-77.782.865	
c) Increase or decrease in inventories	015	-10.884.769	-7.258.538	
d) Other increase or decrease in working capital	016	0	0	
<b>II Cash from operations (ADP 011+012)</b>	<b>017</b>	<b>-20.943.229</b>	<b>-29.084.854</b>	
4 Interest paid	018	-133.312	-383.162	
5 Income tax paid	019	-2.513.247	-3.950.695	
<b>A) NET CASH FLOW FROM OPERATING ACTIVITIES (ADP 017 to 019)</b>	<b>020</b>	<b>-23.589.788</b>	<b>-33.418.711</b>	
<b>Cash flow from investment activities</b>				
1 Cash receipts from sales of fixed tangible and intangible assets	021	896.107	69.947	
2 Cash receipts from sales of financial instruments	022	0	0	
3 Interest received	023	1.375.541	1.255.003	
4 Dividends received	024	0	0	
5 Cash receipts from repayment of loans and deposits	025	474.835	602.257	
6 Other cash receipts from investment activities	026	441.116	275.725	
<b>III Total cash receipts from investment activities (ADP 021 to 026)</b>	<b>027</b>	<b>3.187.599</b>	<b>2.202.932</b>	
1 Cash payments for the purchase of fixed tangible and intangible assets	028	-1.292.410	-1.711.511	
2 Cash payments for the acquisition of financial instruments	029	0	0	
3 Cash payments for loans and deposits for the period	030	-79.634	-216.234	
4 Acquisition of a subsidiary, net of cash acquired	031	-1.844.164	-1.973.755	
5 Other cash payments from investment activities	032	0	-1.974	
<b>IV Total cash payments from investment activities (ADP 028 to 032)</b>	<b>033</b>	<b>-3.216.208</b>	<b>-3.903.474</b>	
<b>B) NET CASH FLOW FROM INVESTMENT ACTIVITIES (ADP 027 +033)</b>	<b>034</b>	<b>-28.609</b>	<b>-1.700.542</b>	
<b>Cash flow from financing activities</b>				
1 Cash receipts from the increase in initial (subscribed) capital	035	0	0	
2 Cash receipts from the issue of equity financial instruments and debt financial instruments	036	0	0	
3 Cash receipts from credit principals, loans and other borrowings	037	69.015.860	55.000.000	
4 Other cash receipts from financing activities	038	0	0	
<b>V Total cash receipts from financing activities (ADP 035 to 038)</b>	<b>039</b>	<b>69.015.860</b>	<b>55.000.000</b>	
1 Cash payments for the repayment of credit principals, loans and other borrowings and debt financial instruments	040	-12.953.029	-43.744.720	
2 Cash payments for dividends	041	-5.379.999	-6.225.110	
3 Cash payments for finance lease	042	-289.074	-299.901	
4 Cash payments for the redemption of treasury shares and decrease in initial (subscribed) capital	043	0	0	

JB π.



5 Other cash payments from financing activities	044	-771.651	-330.659
<b>VI Total cash payments from financing activities (ADP 040 to 044)</b>	<b>045</b>	<b>-19.393.753</b>	<b>-50.600.390</b>
<b>C) NET CASH FLOW FROM FINANCING ACTIVITIES (ADP 039 +045)</b>	<b>046</b>	<b>49.622.107</b>	<b>4.399.610</b>
1 Unrealised exchange rate differences in respect of cash and cash equivalents	047	0	0
<b>D) NET INCREASE OR DECREASE IN CASH FLOWS (ADP 020+034+046+047)</b>	<b>048</b>	<b>26.003.710</b>	<b>-30.719.643</b>
<b>E) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD</b>	<b>049</b>	<b>11.295.726</b>	<b>54.177.660</b>
<b>F) CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD(ADP 048+049)</b>	<b>050</b>	<b>37.299.436</b>	<b>23.458.017</b>

AB J.





"FINANCIAL STATEMENT NOTES  
(are compiled for quarterly reporting periods)

Issuer: MEDIKA d.d.

OIB: 94818858923

Reporting period: [01.01.2023. - 30.06.2023.](#)

Notes to the financial statements for quarterly periods include:

a) an explanation of business events that are significant for understanding the changes in the statement of financial position and business results for the reporting quarter for the issuer's quarter, ie information related to those events is published and relevant information published in the last annual financial report is updated ( paragraphs 15 to 15C of IAS 34 - Financial Reporting for Interim Years),

[The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards as adopted by the European Union \(IFRS\). The consolidated financial statements of the Group have been prepared under the historical cost convention, unless otherwise stated.](#)

[The preparation of consolidated financial statements in conformity with International Financial Reporting Standards as adopted by the European Union \(IFRS\) requires the use of certain critical accounting estimates.](#)

[On 30.06.2023. year in relation to the beginning of the year Medika d.d. increased credit indebtedness by EUR 11.3 million.](#)

[Significant business events and transactions in the observed period, which are important for understanding the changes in the Statement of Financial Position and Business Results are explained in pdf document - Interim Management Report for I-VI 2023 Group Medika, which was published simultaneously on this website Medika dd \[www.medika.hr\]\(http://www.medika.hr\), on the website of the Zagreb Stock Exchange d.d. and submitted to the Official Register of Prescribed Information at the Croatian Financial Services Supervisory Agency.](#)

b) information where access to the latest annual financial statements is provided, in order to understand the information published in the notes to the financial statements prepared for the reporting quarter,

[The notes to the financial statements are included in the audited annual financial statements of the Medika Group. The audited annual financial statements for 2022 are available on the website of Medika d.d. \[www.medika.hr\]\(http://www.medika.hr\), on the website of the Zagreb Stock Exchange d.d. and was submitted to the Official Register of Prescribed Information at the Croatian Financial Services Supervisory Agency.](#)

c) a statement that the same accounting policies are applied in preparing the financial statements for the quarterly period as in the most recent annual financial statements or, if those accounting policies have changed, a description of the nature and effect of the change (paragraph 16A (a) of IAS 34 Financial Reporting for periods during the year),

[The financial statements for Group were prepared on the basis of the same accounting policies, presentations and calculation methods as well as they were in the annual financial statements on December 31, 2022, with the exception of the reporting currency \(for 2022, the functional and reporting currency was HRK, and the amounts are recalculated at the conversion rate of 7.53450\).](#)

d) an explanation of the business results in the event that the issuer performs activities of a seasonal nature (paragraphs 37 and 38 of IAS 34 - Financial Reporting for Periods during the Year)

[The Medika Group does not perform activities of a seasonal nature.](#)

AB 11.



e) other disclosures required by IAS 34 - Financial Reporting for the Periods during the year  
Short-term and long-term receivables from customers, related companies and participating companies amount to EUR 290,4 million and record a increase of 36,23% compared to the beginning of the year due to slower collection and sales growth.

Reclassification:

AOP 119 Liabilities to employees include short-term provisions.

Assets with the right of use are stated within long-term intangible assets by type of assets, while lease liabilities are stated within other long-term and short-term liabilities.

Interest payable on loans is stated within other short-term liabilities.

f) in addition to the above information, the following information shall be disclosed in the notes to the financial statements for the quarterly periods:

1. name, registered office of the undertaking (address), legal form of the undertaking, country of establishment, registration number of the entity, personal identification number and, if applicable, that the undertaking is in liquidation, bankruptcy, summary winding up or extraordinary administration

PARENT COMPANY INFORMATION:

Name of the issuer: Medika d.d.,

Headquarters: Capraška 1, 10000 Zagreb

Legal form: joint stock company

Country of establishment: Republic of Croatia

MBS: 080027531

OIB: 94818858923

2. adopted accounting policies (only an indication of whether there has been a change compared to the previous period)

During the reporting period, the Medika Group did not change its accounting policies compared to the previous year.

3. the total amount of any financial liabilities, guarantees or contingencies not included in the balance sheet, as well as an indication of the nature and form of any actual insurance provided; all liabilities relating to the pensions of an entrepreneur within a group or company related to a participating interest are disclosed separately

For a certain part of liabilities to suppliers, leases and loans (which are shown in the balance sheet), the Medika Group issued bank guarantees or debentures as collateral.

Liabilities from provisions for pensions are presented in the balance sheet in accordance with IAS-19.

4. the amount and nature of individual items of income or expenditure of exceptional size or occurrence

Medika Group in the reporting period 01.01.-30.06.2023. have generated consolidated net sales revenues in the amount of EUR 365,743 thousand (in the period 01.01.-30.06.2022., EUR 297,495 thousand).

5. amounts owed by the entrepreneur and maturing after more than five years, as well as the total debts of the entrepreneur covered by valuable insurance provided by the entrepreneur, with an indication of the type and form of insurance

Medika Group on 30.06.2023. have liabilities over 5 years and are entirely related to operating lease liabilities in the amount of EUR 913 thousand.

Long-term tangible assets with a net book value as of June 30, 2023 are pledged as collateral for the loan amounts to EUR 16,518 thousand.

6. average number of employees during the current period

AB K.



Average number of employees of the Medika Group during the current period 01.01.-30.06.2023. amounts to 953 employees (during the period 01.01.-30.06.2022. the average number of employees was 946 employees).

7. if the entrepreneur in the business year in accordance with the regulations capitalized the cost of salaries in part or in full, information on the amount of total employee costs during the year broken down into the amount directly charged to the period and the amount capitalized in the value of assets during the period. for each part separately states the total amount of net salaries and the amount of taxes, contributions from salaries and contributions to salaries  
The Medika Group did not capitalize the cost of salaries during the reporting period.

8. if provisions for deferred tax, deferred tax balances at the end of the business year and movements of these balances during the business year are recognized in the balance sheet  
Deferred tax assets on 30.06.2023. amounts to EUR 159 thousand and records an increase of EUR 30 thousand from the beginning of the year.

9. the name and registered office of each undertaking in which the undertaking, alone or through a person acting in his own name but on behalf of the undertaking, holds a participating share in the capital, showing the amount of capital held, the amount of total capital and reserves, business years of the undertaking concerned, for which the annual financial statements have been adopted; information on capital and reserves and profit or loss may be omitted if the undertaking in question does not publish its balance sheet and is not under the control of another undertaking  
Medika d.d. has 100% stake in Primus nekretnine d.o.o. and Ljekarna Prima Pharme which holds 100% stake in ZU Ljekarna Šeremet and the associated company ZU Ljekarna Jagatić in which it has a 49% stake.

10. number and nominal value, or if there is no nominal value, the book value of shares or stakes subscribed during the business year within the authorized capital  
No new shares are subscribed during the business year.  
Share capital as at 30.06.2023. is EUR 27,778 thousand and is divided into 30,194 shares. The nominal value of one share is EUR 920,00.

11. the existence of any certificates of participation, convertible debentures, guarantees, options or similar securities or rights, indicating their number and the rights conferring  
The Medika Group has no certificates of participation, convertible debentures, guarantees, options or similar securities or rights.

12. name, registered office and legal form of each undertaking in which the undertaking has unlimited liability  
Not applicable.

13. name and registered office of the undertaking compiling the quarterly consolidated financial statements of the largest group of undertakings in which the undertaking participates as a controlled member of the group  
Not applicable.

14. the name and registered office of the undertaking which draws up the quarterly consolidated financial statements of the smallest group of undertakings in which the undertaking participates as a controlled member and which is also included in the group of undertakings referred to in point 13.  
Not applicable.

15. the place where copies of the quarterly consolidated financial statements referred to in points 13 and 14 can be obtained, provided that they are available  
Not applicable.

MB K.



16. the nature and business purpose of undertakings' arrangements not included in the balance sheet and the financial impact of those arrangements on the undertaking, provided that the risks or rewards of such arrangements are material and the disclosure of such risks or rewards is necessary to assess the undertaking's financial position.

Medika Group has no material arrangements with companies that are not included in the financial statements as at 30.06.2023.

17. the nature and financial impact of significant events that occurred after the balance sheet date and were not reflected in the income statement or balance sheet

The Medika Group has no significant events that occurred after the balance sheet date and are not reflected in the income statement or balance sheet.

Regarding EU restriction measures, which refers to the consequences of exposure and the impact of the Russian invasion of Ukraine, Group declares that it does not have a direct business relationship with entities from Russia or Ukraine, nor is it otherwise directly exposed to those entities in its business.

Nevertheless, the Group's management estimates that an indirect impact on the Group's operations is possible due to the impact on the entire economy on global level, mainly due to the increase in the price of energy products, both raw materials, interest rates and inflation that have increased further with the Russian invasion of Ukraine. Given the uncertain extent of the impact on the economy, the Group monitors developments and assesses the impact on business, financial situation and cash flows.

“

AK J.

Zagreb, 26 July 2023

Pursuant to the articles 462 to 471 of the Capital market Law (Official Gazette 65/18) President of the Management Board Jasminko Herceg provides

**STATEMENT OF LIABILITY FOR PREPARING FINANCIAL STATEMENTS OF  
ISSUER**

Unaudited unconsolidated and consolidated financial statements of Medika d.d. have been prepared pursuant to the International Financial Reporting Standards (IFRS) and Croatian Accounting Law.

Unaudited unconsolidated and consolidated financial statements for the period 01 January to 30 June 2023 present true and fair view of assets and liabilities, financial position, profit or loss of the Company and the Group.

The interim management report for the unaudited financial statements for the period 01 January to 30 June 2023 presents fair presentation of development and results of the operations and position of the Company and the Group with description of significant risks and uncertainties for the Company and the Group.

Jasminko Herceg  
President of the Management Board

<sup>3</sup> **Medika** d.d.  
ZAGREB, Capraška 1